Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Characterization of CD56bright NK cells in daclizumab HYP-treated RRMS patients
Visualization of myelination in GFP-transgenic zebrafish.
Laquinimod modulates B cells and their regulatory effects on T cells in Multiple Sclerosis.
Teva and Active Biotech to continue with the development of NERVENTRA® (laquinimod) for multiple sclerosis following confirmation of CHMP opinion
Glatiramer Acetate administration does not reduce damage after cerebral ischemia in mice.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Pervasive Axonal Transport Deficits in Multiple Sclerosis Models.
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
Receptos doses first patient in Phase 2 trial for RPC1063 in ulcerative colitis
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Alemtuzumab benefits hard-to-treat MS patients
Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
Zebrafish myelination: a transparent model for remyelination?
Limit cycle oscillations in standing human posture.
Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Interferon β-1b directly modulates human neural stem/progenitor cell fate.
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
Multiple Sclerosis and Pregnancy: Current Considerations.
New Drugs Online report for idebenone
Focal vibration in neurorehabilitation.
The immunopathology of multiple sclerosis: an overview.
Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.

Pages